Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $18.11 million. The enterprise value is $16.72 million.
| Market Cap | 18.11M |
| Enterprise Value | 16.72M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 4.61 million shares outstanding. The number of shares has increased by 44.12% in one year.
| Current Share Class | 4.61M |
| Shares Outstanding | 4.61M |
| Shares Change (YoY) | +44.12% |
| Shares Change (QoQ) | +1.09% |
| Owned by Insiders (%) | 25.25% |
| Owned by Institutions (%) | 32.93% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.53 |
| Forward PS | n/a |
| PB Ratio | 3.29 |
| P/TBV Ratio | 3.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82
| Current Ratio | 0.82 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.22% and return on invested capital (ROIC) is -62.46%.
| Return on Equity (ROE) | -98.22% |
| Return on Assets (ROA) | -52.33% |
| Return on Invested Capital (ROIC) | -62.46% |
| Return on Capital Employed (ROCE) | -134.15% |
| Weighted Average Cost of Capital (WACC) | 13.86% |
| Revenue Per Employee | $1.90M |
| Profits Per Employee | -$6.71M |
| Employee Count | 1 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.83% in the last 52 weeks. The beta is 1.75, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.75 |
| 52-Week Price Change | +57.83% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 2.43 |
| Relative Strength Index (RSI) | 59.52 |
| Average Volume (20 Days) | 31,881 |
Short Selling Information
The latest short interest is 44,969, so 0.98% of the outstanding shares have been sold short.
| Short Interest | 44,969 |
| Short Previous Month | 34,811 |
| Short % of Shares Out | 0.98% |
| Short % of Float | 3.82% |
| Short Ratio (days to cover) | 2.12 |
Income Statement
In the last 12 months, CYCN had revenue of $1.90 million and -$6.71 million in losses. Loss per share was -$1.73.
| Revenue | 1.90M |
| Gross Profit | 303,000 |
| Operating Income | -6.82M |
| Pretax Income | -6.71M |
| Net Income | -6.71M |
| EBITDA | n/a |
| EBIT | -6.82M |
| Loss Per Share | -$1.73 |
Balance Sheet
The company has $1.39 million in cash and no debt, with a net cash position of $1.39 million or $0.30 per share.
| Cash & Cash Equivalents | 1.39M |
| Total Debt | n/a |
| Net Cash | 1.39M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 5.09M |
| Book Value Per Share | 1.20 |
| Working Capital | -329,000 |
Cash Flow
In the last 12 months, operating cash flow was -$4.45 million and capital expenditures -$66,000, giving a free cash flow of -$4.52 million.
| Operating Cash Flow | -4.45M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -4.52M |
| FCF Per Share | -$0.98 |
Margins
| Gross Margin | 15.95% |
| Operating Margin | -359.16% |
| Pretax Margin | -353.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.12% |
| Shareholder Yield | -44.12% |
| Earnings Yield | -37.04% |
| FCF Yield | -24.95% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 467.81% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
CYCN has an Altman Z-Score of -56.01 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -56.01 |
| Piotroski F-Score | 2 |